Sudarshan Pharma Set for NSE Main Board Listing Following BSE SME Platform Migration

Key numbers

Market Cap	₹752.06 CrSmall Cap
PE TTM	32.27xSector PE 34.89x
Net Profit Growth	35.5%YoY (Jun 2026)
Promoter Holding	57.81%Latest Quarter

Key highlights

• Listing and trading on NSE Capital Market Segment to commence on October 27, 2026
• Company will trade under the symbol SUDARSHAN with ISIN INE00TV01023
• Total of 25,44,70,600 equity shares of Re 1 each admitted for dealings
• Reported 35.5% YoY growth in net profit for the quarter ended June 30, 2026
• Strategic shift from SME platform to provide higher liquidity and institutional access

Strategic Migration to NSE Main Board

Sudarshan Pharma Industries is transitioning from the BSE SME platform to the Capital Market Segment (Main Board) of the National Stock Exchange of India. This move, effective from October 27, 2026, involves the listing of 25,44,70,600 fully paid-up equity shares with a face value of Re 1 each. The company will trade under the series EQ.

The migration follows the company's formal application and a series of corporate governance milestones aimed at enhancing market visibility and broadening the investor base beyond the SME segment limitations. As of the latest filings, the equity structure includes specific lock-in periods for approximately 13.72 crore shares extending until late 2027 and early 2028.

Financial Performance and Operational Metrics

• Operating revenue for the quarter ended June 30, 2026, reached ₹174.42 crore, a 20.1% increase year-on-year
• Net profit for the same quarter rose to ₹5.36 crore, up from ₹3.95 crore in the previous year's corresponding period
• The company maintains an operating profit margin of 9.12% as of the June 2026 quarter
• Annual revenue for the trailing twelve months stands at ₹732.21 crore with a net profit of ₹24.63 crore
• Promoter holding remains stable at 57.81%, while FII holding has increased to 21.94% as per recent records

Recent Corporate Developments

In the months leading up to the migration, Sudarshan Pharma has been active in restructuring its portfolio and capital base. On September 28, 2026, the company completed the divestment of its 51% stake in Ishwari Healthcare Private Limited for ₹1.40 crore. This followed the conversion of US$ 1.5 million in Foreign Currency Convertible Bonds (FCCBs) into equity shares in August 2026.

While the company recently terminated a proposed acquisition of a 9.50% stake in US-based MedTherapy Biotechnology on October 7, 2026, it remains focused on domestic expansion, including an MOU to acquire a 76% stake in a pharmaceutical target based in Visakhapatnam.

NSE Listing Notification Details

We are pleased to inform you that the equity shares of the Company shall be listed and admitted to dealings on the Exchange (Capital Market Segment) w.e.f. October 27, 2026 pursuant to Migration from SME Platform of BSE.

What to watch next

• Release of financial results for the quarter and half-year ended September 30, 2026
• Completion of the remaining 30% equity stake acquisition in Sudarshan Maven Pharma by December 31, 2026
• Finalization of the 76% equity stake acquisition in the Visakhapatnam pharmaceutical target

Sudarshan Pharma Industries · financial snapshot

Share price	₹31.25
Market capitalisation	₹752.06 Cr
Revenue (annual)	₹703.06 Cr
Net profit (annual)	₹23.30 Cr
Revenue (latest quarter)	₹174.42 Cr-21.05% vs previous quarter
Net profit (latest quarter)	₹5.36 Cr-49.99% vs previous quarter
P/E (TTM)	32.27×Sector 34.89×
Promoter holding	57.81%-1.12% QoQ
FII holding	21.94%Current quarter

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.